.gif)
ERYTECH Pharma, the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, received a new patent in the United States.
A United States patent entitled “Erythrocytes Containing Arginine Deiminase” has been issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 9,125,876. It covers the use of ERY-ADI, a tumor starvation product candidate arising from ERYTECH’s encapsulation platform.
The patent received 363 days of patent term adjustment (PTA), and with that PTA, has a term in the United States through at least April 2027. The term of this patent may also be eligible for limited patent term extension in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The counterparts of this patent have already been issued in Europe, China, Japan, Canada, Korea and Australia.
ERYTECH’s patent portfolio consists of 12 patent families covering its technology platform and applications in and outside oncology and a license from the U.S. National Institutes of Health covering a diagnostic method to predict the efficacy of L-asparaginase.
Subscribe to PharmaTutor News Alerts by Email >>
